REGULATED PRESS RELEASE published on 05/15/2025 at 07:00, 1 year 2 months ago Biophytis Highlights Innovative Approach to Obesity Treatment During Key ECO 2025 Presentation Biophytis highlights innovative approach to obesity treatment at ECO 2025 presentation, showcasing promising results of BIO101 drug candidate targeting muscle loss in obese patients Biophytis Obesity Treatment BIO101 ECO 2025 Muscle Loss
BRIEF published on 04/25/2025 at 18:05, 1 year 3 months ago Biophytis Delays Release of 2024 Financial Statements Financial Statements Biophytis Refinancing 2024 Delay
REGULATED PRESS RELEASE published on 04/25/2025 at 18:00, 1 year 3 months ago Postponement of the publication of the annual financial statements Biophytis announces postponement of annual financial statements publication due to refinancing operation. Company aims to release by end of May 2025 Financial Statements Biophytis 2024 Postponement Refinancing Operation
BRIEF published on 04/22/2025 at 07:05, 1 year 3 months ago Biophytis Aims for Enhanced Mobility in Obesity Treatment Biophytis Obesity Treatment Muscle Preservation GLP-1 Therapies Biotechnology Market
REGULATED PRESS RELEASE published on 04/22/2025 at 07:00, 1 year 3 months ago Biophytis targets mobility restoration in patients with obesity Biophytis strengthens position in developing treatments for age-related muscle function loss in obesity care by focusing on quality weight loss and mobility restoration with BIO101 and GLP-1 therapies Biophytis Muscle Function Obesity Care Quality Weight Loss Mobility Restoration
PRESS RELEASE published on 04/22/2025 at 06:59, 1 year 3 months ago Biophytis targets mobility restoration in patients with obesity Biophytis focuses on preserving muscle function in obesity patients treated with GLP-1 therapies by developing BIO101. The aim is to improve quality of weight loss and mobility Biophytis BIO101 Obesity Muscle Function GLP-1 Therapies
BRIEF published on 04/09/2025 at 07:05, 1 year 3 months ago Biophytis Initiates Phase 2 OBA Clinical Trial for Obesity Treatment Biophytis Obesity Treatment Clinical Trial BIO101 Partnership Goal
REGULATED PRESS RELEASE published on 04/09/2025 at 07:00, 1 year 3 months ago Biophytis Confirms the Launch of the Phase 2 OBA Clinical Trial in Obesity Biophytis confirms the Phase 2 OBA Clinical Trial launch in obesity, continuing development of BIO101 to reduce muscle strength loss. Seeking pharmaceutical partner for co-development Biophytis BIO101 Obesity Pharmaceutical Partner Phase 2 OBA Clinical Trial
PRESS RELEASE published on 04/09/2025 at 06:59, 1 year 3 months ago Biophytis Confirms the Launch of the Phase 2 OBA Clinical Trial in Obesity Biophytis confirms the launch of the Phase 2 OBA Clinical Trial in Obesity in 2025. The study aims to evaluate the efficacy of BIO101 in reducing muscle strength loss caused by GLP-1 agonists in obese patients Biophytis BIO101 Obesity Muscle Strength Phase 2 OBA Clinical Trial
BRIEF published on 03/28/2025 at 22:05, 1 year 4 months ago Biophytis Finalizes €2.6 Million Private Placement Private Placement Biophytis Warrants New Shares Euronext Growth
Published on 08/06/2026 at 11:00, 1 hour 16 minutes ago Blue Lagoon Files Annual Financial Statements and Provides Comment on Temporary Cease Trade Order
Published on 08/06/2026 at 08:05, 4 hours 11 minutes ago Tocvan Drills Significant Discovery On Mezquite Trend Gran Pilar 215M Of 0.6 G/T AU, From 36.6M Downhole
Published on 08/06/2026 at 03:35, 8 hours 41 minutes ago Tunkillia Upgrade Drilling – 39,000m Phase 2 Complete Targeting JORC Resource Classification Upgrades; PFS Underway
Published on 08/06/2026 at 01:40, 10 hours 36 minutes ago Taranis Identifies a Hydrothermally Altered, Sulfide-Bearing Intrusive Stock Associated with Historic Gold-Silver Occurrence and Connected to Thor
Published on 08/05/2026 at 23:40, 12 hours 36 minutes ago Galantas Gold Secures Key Permitting Approvals for Andacollo Gold Project
Published on 08/06/2026 at 12:05, 10 minutes ago CULTURAL DISRUPTORS AND CULINARY ICONS UNVEILED AS THE GLOBAL JURY FOR THE S.PELLEGRINO YOUNG CHEF ACADEMY COMPETITION 2026-27
Published on 08/06/2026 at 11:30, 45 minutes ago Partners Group to become majority shareholder in data center power solutions provider AVK and accelerate future growth
Published on 08/06/2026 at 11:05, 1 hour 10 minutes ago ABB invests in LevelTen Energy to advance clean energy procurement
Published on 08/06/2026 at 11:05, 1 hour 10 minutes ago IIFL Capital partners with Flytxt to leverage Agentic AI for sustainable AUM growth
Published on 08/06/2026 at 08:00, 4 hours 16 minutes ago EURAZEO ENTERS INTO EXCLUSIVE DISCUSSIONS WITH PARTNERS GROUP REGARDING THE CONTEMPLATED SALE OF ITS STAKE IN AROMA-ZONE AND ITS REINVESTMENT
Published on 08/05/2026 at 18:00, 18 hours 16 minutes ago Information concerning the total number of voting rights and shares in the share capital as of July 31, 2026
Published on 08/05/2026 at 17:49, 18 hours 26 minutes ago Mersen: Number of shares and voting rights as of July 31, 2026
Published on 08/05/2026 at 17:45, 18 hours 31 minutes ago Information concerning the total number of voting rights and shares 2026 07 31
Published on 08/05/2026 at 17:45, 18 hours 31 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
